Oncolytics Biotech (ONCY) to Announce Quarterly Earnings on Friday

Oncolytics Biotech (NASDAQ:ONCY) is expected to post its Q2 2026 results after the market closes on Friday, August 14th. Analysts expect the company to announce earnings of ($0.0538) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Oncolytics Biotech (NASDAQ:ONCY) last released its earnings results on Thursday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). On average, analysts expect Oncolytics Biotech to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock opened at $0.82 on Wednesday. The stock has a market capitalization of $97.87 million, a P/E ratio of -2.65 and a beta of 1.13. Oncolytics Biotech has a 12-month low of $0.73 and a 12-month high of $1.51. The firm’s 50-day moving average is $0.86 and its two-hundred day moving average is $0.93.

Institutional Investors Weigh In On Oncolytics Biotech

Several hedge funds and other institutional investors have recently modified their holdings of ONCY. Citadel Advisors LLC acquired a new stake in shares of Oncolytics Biotech during the 3rd quarter valued at approximately $535,000. XTX Topco Ltd bought a new stake in shares of Oncolytics Biotech in the 4th quarter worth approximately $69,000. Virtu Financial LLC acquired a new position in Oncolytics Biotech during the 4th quarter valued at approximately $68,000. Tocqueville Asset Management L.P. acquired a new position in Oncolytics Biotech during the 4th quarter valued at approximately $63,000. Finally, CIBC Private Wealth Group LLC bought a new position in Oncolytics Biotech during the 4th quarter worth $44,000. Institutional investors own 6.82% of the company’s stock.

Analyst Upgrades and Downgrades

ONCY has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Oncolytics Biotech in a research report on Tuesday, July 14th. Wall Street Zen downgraded shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard?of?care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non?small cell lung cancer and head and neck cancers.